Accepting risk in clinical research: Is the gene therapy field becoming too risk-averse?

Molecular Therapy

Volumn 17, Issue 11, 2009, Pages 1842-1848

  Deakin, Claire T ^a,b   Alexander, Ian E ^a,b,c   Kerridge, Ian ^c,d  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FEAR; GENE THERAPY; GENOTOXICITY; HUMAN; LEGAL ASPECT; MUTAGENESIS; PATIENT SAFETY; RESEARCH ETHICS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; RISK;

EID: 70449527808     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.223     Document Type: Review

References (93)

1. US Congress Senate Committee on Health, Education, labor and Pensions and the Subcommittee on Public Health (2002). Gene therapy: Is there oversight for patient safety? 106th Congress, 2nd session, 2 February 2002.
2. Williams, DA (2007). RAC reviews serious adverse event associated with AAV therapy trial. Mol Ther 15: 2053-2054.
3. Wilson, JM (2008). Adverse events in gene transfer trials and an agenda for the new year. Hum Gene Ther 19: 1-2.
4. American Society of Gene Therapy (2008). ASGT position statement on informed consent. . Accessed 7 May 2009.
5. King, NM (2002). RAC oversight of gene transfer research: A model worth extending? J Law Med Ethics 30: 381-389.
6. Caplan, AC (2008). If it's broken, shouldn't it be fixed? Informed consent and initial clinical trials of gene therapy. Hum Gene Ther 19: 5-6.
7. Shalala, D (2000). Protecting research subjects-what must be done. N Engl J Med 343: 808-810.
8. Frewer, LJ (2003). Trust, transparency, and social context: Implications for social amplification of risk. In: Pidgeon, N, Kasperson, RE and Slovic, P (eds). The Social Amplification of Risk. Cambridge University Press: Cambridge, pp. 123-137.
9. Eldridge J and Reilley J. (2003). Risk and relativity: BSE and the British media. In: Pidgeon, N, Kasperson, RE and Slovic, P (eds). The Social Amplification of Risk, Cambridge University Press, Cambridge pp 138-155.
10. Anderson, WF (1989). Human gene therapy: Why draw a line? J Med Philos 14: 681-693.
11. Gaskell, G, Allum, N, Bauer, M, Jackson, J, Howard, S and Lindsey, N (2003). Ambivalent GM nation? Public attitudes to biotechnology in the UK, 1991-2002, Life Sciences in European Society Report. London School of Economics and Political Science: London, 19 pp.
12. Biotechnology Australia (2005). Public awareness research 2005: Human health. . Accessed 18 June 2009.
13. The New York Times (2009). Times topics: Jesse Gelsinger. . Accessed 7 May 2009.
14. US Food and Drug Administration Center for Drug Evaluation and Research (2009). Adverse event reporting system patient outcomes by year. . Accessed 18 September 2009.
15. International Society for Stem Cell Research (2008). Guidelines for clinical translation of stem cells. . Accessed 18 June 2009.
16. US President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research (1982). Splicing life: A report on the social and ethical issues of genetic engineering with human beings. Library of Congress card number 83-600500.
17. Kimmelman, J (2008). The ethics of human gene transfer. Nat Rev Genet 9: 239-244.
18. Jaeger, CC, Renn, O, Rosa, EA and Weber, T (2001). Risk, Uncertainty, and Rational Action. Earthscan: London, 320 pp.
19. Royal Society for the Prevention of Accidents (1983). Risk Assessment: A Study Group Report. Royal Society: London.
20. Kaplan, S and Garrick, BJ (1981). On the quantitative definition of risk. Risk Anal 1: 11-27.
21. Chicken, JC and Posner, T (1998). The Philosophy of Risk. Thomas Telford: London, 194 pp.
22. Garland, D (2003). The rise of risk. In: Ericson RV and Doyle A (eds). Risk and Morality. University of Toronto Press: Toronto, pp. 48-86.
23. Denney, D (2005). Risk and Society. Sage: London, 220 pp.
24. Tulloch, J and Lupton, D (2003). Risk and Everyday Life. Sage: London, 140 pp.
25. Althaus, CE (2005). A disciplinary perspective on the epistemological status of risk. Risk Anal 25: 567-588.
26. Slovic, P (2000). The Perception of Risk. Earthscan: London, 473 pp.
27. Ortwin, R and Rohrmann, B (2000). Cross-cultural Risk Perception: A Survey of Empirical Studies. Kluwer: Dordrecht/London, 240 pp.
28. Dosman, DM, Adamowicz, WL and Hrudey, SE (2001). Socioeconomic determinants of health- and food safety-related risk perceptions. Risk Anal 21: 307-317.
29. Glendon, AI, Dorn, L, Davies, DR, Matthews, G and Taylor, RG (1996). Age and gender differences in perceived accident likelihood and driver competences. Risk Anal 16: 755-762.
30. Slovic, P, Fischhoff, B and Lichtenstein, S (1980). Facts and fears: understanding perceived risk. In: Schwing, R and Albers, W (eds). Societal Risk Assessment: How Safe is Safe Enough. Plenum: New York, pp. 181-214.
31. Slovic, P (1987). Perception of risk. Science 236: 280-285.
32. Weinstein, ND (1984). Why it won't happen to me: Perceptions of risk factors and susceptibility. Health Psychol 3: 431-457.
33. Perel, P, Roberts, I, Sena, E, Wheble, P, Briscoe, C, Sandercock, P et al. (2007). Comparison of treatment effects between animal experiments and clinical trials: Systematic review. BMJ 334: 197.
34. Hackam, DG and Redelmeier, DA (2006). Translation of research evidence from animals to humans. JAMA 296: 1731-1732.
35. Macleod, MR, O'Collins, T, Howells, DW and Donnan, GA (2004). Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35: 1203-1208.
36. American Society of Gene Therapy (2003). Report from the ASGT Ad Hoc Committee on retroviral-mediated gene transfer to hematopoietic stem cells. . Accessed 18 June 2009.
37. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
38. Mingozzi, F, Meulenberg, J, Hui, D, Basner-Tschkarajan, E, de Jong, A, Pos, P et al. (2007). Capsid-specific T cell responses in humans upon intramuscular admininstration of an AAV-1 vector expressing LPLS447X transgene. Hum Gene Ther 18: 991-992.
39. LaFollette, H and Shanks, N (1996). Brute Science: Dilemmas of Animal Experimentation. Routledge: London, 304 pp.
40. 59th World Medical Association General Assembly (2008). Declaration of Helsinki. . Accessed 18 June 2009.
41. Dresser, R (2001). When Science Offers Salvation: Patient Advocacy and Research Ethics. Oxford University Press: New York, 215 pp.
42. Epstein, S (1996). Impure Science: AIDS, Activism, and the Politics of Knowledge. University of California Press: Berkeley, 466 pp.
43. Lowenstein, PR (2008). Clinical trials in gene therapy: Ethics of informed consent and the future of experimental medicine. Curr Opin Mol Ther 10: 428-430.
44. Lowenstein, PR (2008). A call for physiopathological ethics. Mol Ther 16: 1771-1772.
45. Kimmelman, J (2005). Recent developments in gene transfer: Risk and ethics. BMJ 330: 79-82.
46. Kimmelman, J (2007). Stable ethics: Enrolling non-treatment-refractory volunteers in novel gene transfer trials. Mol Ther 15: 1904-1906.
47. Bennett, J, Maguire, AM, Fraser Wright, J, Marshall, KA, Bennicelli, J, Leroy, BP et al. (2009). Gene therapy-mediated reversal of congenital blindness: Demonstration of efficacy in a phase 1 safety trial. In: 12th Annual Meeting of the American Society of Gene Therapy, Plenary Abstract Session, May 29, San Diego.
48. Matsui, D, Kwan, C, Steer, E and Rieder, MJ (2003). The trials and tribulations of doing drug research in children. CMAJ 169: 1033-1034.
49. Meadows, M (2003). Greater access to generic drugs. New FDA initiatives to improve drug reviews and reduce legal loopholes. FDA Consum 37: 12-17.
50. Caldwell, PH, Murphy, SB, Butow, PN and Craig, JC (2004). Clinical trials in children. Lancet 364: 803-811.
51. Stolberg, SG (1999). The biotech death of Jesse Gelsinger. N Y Times Mag: 136-140, 149.
52. Wilson, JM (2009). Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96: 151-157.
53. Gillick v West Norfolk & Wisbech HA [1986] 1 AC 112.
54. Secretary of the Department of Health and Community Services v JWB and SMB (Marion's case) (1992) 175 CLR 218.
55. Geller, G, Tambor, ES, Bernhardt, BA, Fraser, G and Wissow, LS (2003). Informed consent for enrolling minors in genetic susceptibility research: A qualitative study of at-risk children's and parents' views about children's role in decision-making. J Adolesc Health 32 260-271.
56. US Department of Health and Human Services (2005). Code of Federal Regulations. Code 45, Section 46.404-46.407.
57. Glass, KC and Binik, A (2008). Rethinking risk in pediatric research. J Law Med Ethics 36: 567-576.
58. Wendler, D, Belsky, L, Thompson, KM and Emanuel, EJ (2005). Quantifying the federal minimal risk standard: Implications for pediatric research without a prospect of direct benefit. JAMA 294: 826-832.
59. US Department of Health and Human Services Food and Drug Administration (2002). Notice of opportunity for hearing. . Accessed 18 June 2009.
60. Sinha, SK, Lacaze-Masmonteil, T, Valls i Soler, A, Wiswell, TE, Gadzinowski, J, Hajdu, J et al.; Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group (2005). A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 115: 1030-1038.
61. Kanter, KR, Miller, BE, Cuadrado, AG and Vincent, RN (1995). Successful application of the Norwood procedure for infants without hypoplastic left heart syndrome. Ann Thorac Surg 59: 301-304.
62. Enns, GM, Berry, SA, Berry, GT, Rhead, WJ, Brusilow, SW and Hamosh, A (2007). Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 356: 2282-2292.
63. Mochel, F, DeLonlay, P, Touati, G, Brunengraber, H, Kinman, RP, Rabier, D et al. (2005). Pyruvate carboxylase deficiency: Clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab 84: 305-312.
64. Horn, A, Thompson, C, Woods, D, Nel, A, Bekker, A, Rhoda, N et al. (2009). Induced hypothermia for infants with hypoxic-ischemic encephalopathy using a servo-controlled fan: An exploratory pilot study. Pediatrics 123: E1090-e1098.
65. Mercer, BM, Miodovnik, M, Thurnau, GR, Goldenberg, RL, Das, AF, Ramsey, RD et al. (1997). Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 278: 989-995.
66. Whitelaw, A, Pople, I, Cherian, S, Evans, D and Thoresen, M (2003). Phase 1 trial of prevention of hydrocephalus after intraventricular hemorrhage in newborn infants by drainage, irrigation, and fibrinolytic therapy. Pediatrics 111: 759-765.
67. Juul, SE, McPherson, RJ, Bauer, LA, Ledbetter, KJ, Gleason, CA and Mayock, DE (2008). A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: Pharmacokinetics and safety. Pediatrics 122: 383-391.
68. Weiss Roberts, L (2002). Informed consent and the capacity for voluntarism. Am J Psychiatry 159: 705-712.
69. Iltis, A (2006). Lay concepts in informed consent to biomedical research: The capacity to understand and appreciate risk. Bioethics 20: 180-190.
70. Timmermans, DR, Ockhuysen-Vermey, CF and Henneman, L (2008). Presenting health risk information in different formats: The effect on participants' cognitive and emotional evaluation and decisions. Patient Educ Couns 73: 443-447.
71. Cox, K (2002). Informed consent and decision-making: Patients' experiences of the process of recruitment to phases I and II anti-cancer drug trials. Patient Educ Couns 46: 31-38.
72. Timmermans, D, Molewijk, B, Stiggelbout, A and Kievit, J (2004). Different formats for communicating surgical risks to patients and the effect on choice of treatment. Patient Educ Couns 54: 255-263.
73. Zikmund-Fisher, BJ, Ubel, PA, Smith, DM, Derry, HA, McClure, JB, Stark, A et al. (2008). Communicating side effect risks in a tamoxifen prophylaxis decision aid: The debiasing influence of pictographs. Patient Educ Couns 73: 209-214.
74. Hoffrage, U and Gigerenzer, G (1998). Using natural frequencies to improve diagnostic inferences. Acad Med 73: 538-540.
75. Reynolds, WW and Nelson, RM (2007). Risk perception and decision processes underlying informed consent to research participation. Soc Sci Med 65: 2105-2115.
76. Canterbury v Spence (1975) 464 F.2d 772.
77. Reibl v Hughes [1980] 2 S.C.R. 880.
78. Sidaway v Governors of the Bethlem Royal Hospital [1985] AC 871.
79. Rogers v Whitaker (1992) 175 CLR 479.
80. Faden, RR, Beauchamp, TL and King, NMP (1986). A History and Theory of Informed Consent. Oxford University Press: New York, 392 pp.
81. Berg, JW, Appelbaum, PS, Lidz, CW and Parker, LS (2001). Informed Consent. Oxford University Press: New York, 340 pp.
82. Kahn, J (2008). Informed consent in human gene transfer clinical trials. Hum Gene Ther 19: 7-8.
83. US National Institutes of Health Office of Biotechnology Activities (2003). NIH Guidance on Informed Consent for Gene Transfer Research. . Accessed 18 June 2009.
84. Henderson, GE, Easter, MM, Zimmer, C, King, NM, Davis, AM, Rothschild, BB et al. (2006). Therapeutic misconception in early phase gene transfer trials. Soc Sci Med 62: 239-253.
85. King, NM, Henderson, GE, Churchill, LR, Davis, AM, Hull, SC, Nelson, DK et al. (2005). Consent forms and the therapeutic misconception: the example of gene transfer research. IRB 27: 1-8.
86. Kimmelman, J and Levenstadt, A (2005). Elements of style: Consent form language and the therapeutic misconception in phase 1 gene transfer trials. Hum Gene Ther 16: 502-508.
87. Kim, SY, Holloway, RG, Frank, S, Wilson, R and Kieburtz, K (2008). Trust in early phase research: Therapeutic optimism and protective pessimism. Med Health Care Philos 11: 393-401.
88. Appelbaum, PS, Roth, LH and Lidz, C (1982). The therapeutic misconception: Informed consent in psychiatric research. Int J Law Psychiatry 5: 319-329.
89. Appelbaum, PS, Roth, LH, Lidz, CW, Benson, P and Winslade, W (1987). False hopes and best data: Consent to research and the therapeutic misconception. Hastings Cent Rep 17: 20-24.
90. Kimmelman, J and Palmour, N (2005). Therapeutic optimism in the consent forms of phase 1 gene transfer trials: An empirical analysis. J Med Ethics 31: 209-214.
91. Churchill, LR, Collins, ML, King, NM, Pemberton, SG and Wailoo, KA (1998). Genetic research as therapy: Implications of "gene therapy" for informed consent. J Law Med Ethics 26: 38-47, 3.
92. Bergenmar, M, Molin, C, Wilking, N and Brandberg, Y (2008). Knowledge and understanding among cancer patients consenting to participate in clinical trials. Eur J Cancer 44: 2627-2633.
93. Gullo, K (2005). New survey shows public perception of opportunity to participate in clinical trials has decreased slightly from last year. Harris Interact Healthcare News 5: 1-14.